IPHARMA was authorized to conduct the Phase IIa clinical trial of the medicinal product VM-1011
On September 12, 2016, IPHARMA was authorized by the Ministry of Health of the Russian Federation to conduct the Phase IIa clinical trial of the medicinal product VM-1011.
Protocol № HBV-VM1011-02 "A partially-blind randomized comparative pilot clinical trial of antiviral activity, safety and dosing of VM-1011 compared to tenofovir in treatment-naive patients with chronic viral hepatitis B".
The aim of the clinical trial is to studythe antiviral activity, safety and dosing of VM-1011 compared to tenofovir in patients with chronic viral hepatitis B.
The leading organization in conducting the clinical trial is the Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Federal Service on Custimer’s Rights protection and Human Well-being Surveillance.
The investigational drug developer - Viriom comany - is a member of ChemRar group of companies and is specialized in developing innovative antiviral drugs.
Organization and development of clinical trials in virology is one of the most important fields of concern in IPHARMA company (about 15 Phase I-III clinical trials in patients with hepatitis B and C, HIV, flue, etc.).